Mutaflor oral suspension 1ml x 5 ampoules — Made in Germany — Free Delivery

Pharmacodynamics. The active active ingredient is a strain of non-pathogenic bacteria that belong to the species escherichia coli (e. Coli), in a living and multiplying form: e. coli strain nissle 1917. with the help of special adhesive organelles (such as f-1a, f-1c and curly fimbriae), the strain has the ability to attach to the mucous membrane of the large intestine and form microcolonies in the form of biofilms. due to the presence of flagella, bacteria have inherent mobility, which gives them an advantage in colonizing the large intestine. The effects of the preparation Mutaflor (E. coli strain nissle 1917) have been determined in in vitro and in vivo experiments, as well as in clinical studies. such effects and mechanisms of action have been established.

Antimicrobial properties (antagonism): E. coli strain Nissle 1917 forms antimicrobial substances (microcins), which, on the one hand, are responsible for direct antagonism against pathogens, as well as for the resistance of the strain, the duration of which exceeds that of the actual oral administration of the preparation. In addition, the strain has an inhibitory effect on the invasion of enteroinvasive pathogens into the mucous membrane of the large intestine.

Stabilization of the mucous barrier of the large intestine. In experiments on cell cultures of colon epithelial cells of E. coli, the Nissle 1917 strain demonstrated the ability to stabilize the barrier function of the epithelium and normalize the increased permeability of the intestinal mucosa in general. This strengthening of the barrier function is a consequence of the stimulation of the synthesis of the fixing protein (ZO-2) and the formation with its help of strong intercellular contacts.

E. coli strain Nissle 917 has immunomodulatory properties

In vitro and in vivo studies have shown that the immunomodulatory ability of E. coli strain Nissle 1917 works both at the humoral and cellular levels of the immune system in newborns or in patients, in cases with healthy individuals, the immunomodulatory efficiency is expressed only to a small extent.

1. Influence on the specific immune system

In premature and full-term infants, after colonization (colonization) of the intestine with bacteria E. coli strain Nissle 1917, an early increase in immunocompetence was revealed, as indicated by a significant increase in the level of IgA and IgM in fecal filtrates and blood serum. In contrast, there was no increase in serum IgG levels. Some studies confirm an increase in the level of IgA in saliva. It was found that oral administration of E. coli strain Nissle 1917 is also a stimulator of a cell-mediated immune response in premature infants.

2. Influence on the non-specific immune system

Experiments in vitro and ex vivo revealed a significant increase in the secretory and cytotoxic activity of macrophages. In addition, ex vivo demonstrated an increase in the cytotoxic properties of macrophages directed against intracellular parasites, and, consequently, a stronger protection against intracellular infectious agents. In vivo, a prophylactic effect has been established for systemic infections.

In preterm infants, oral ingestion of E. coli strain Nissle 1917 has also been shown to stimulate nonspecific natural immunity.

Prokinetic properties. E. coli strain Nissle 1917 during metabolism synthesizes short-chain fatty acids, which are necessary for the optimal energy balance of the mucous membrane of the large intestine. They stimulate intestinal motility and blood circulation in its mucous membrane and enhance the absorption of sodium and chlorine ions. Stimulation of motility, which is probably due to the action of acetic acid of bacterial origin, plays an important role in the treatment of chronic constipation.